| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.40B | -11.2% |
| Gross profit | ¥0.33B | — |
| Operating income | ¥-0.11B | — |
| Net income | ¥-0.09B | -265.1% |
| Gross margin | 23.3% | Net margin -6.2% |
| Revenue Q/Q | -43.3% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥1.07B | 76.7% |
| R&D | ¥0.08B | 5.9% |
| SG&A | ¥0.31B | 22.2% |
| Tax & other | ¥-0.02B | -1.5% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
金城医药 ・ 开尔新材 ・ 方直科技 ・ 上海新阳 ・ ST美晨 ・ 冠昊生物 ・ 东宝生物 ・ 飞力达 ・ 瑞丰光电 ・ 佳云科技 ・ 瑞丰高材 ・ 迪安诊断
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies